Business
Press Release Jan 25 2024
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 25, 2024, titled "Jiangsu Alphamab Biopharmaceuticals, 3D Medicines (Beijing) and Glenmark announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World".
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":" Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 25, 2024, titled \"Jiangsu Alphamab Biopharmaceuticals, 3D Medicines (Beijing) and Glenmark announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World\". View Attachment","length":457,"tagName":"div"}]